Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09OTF
|
||||
| Former ID |
DIB000709
|
||||
| Drug Name |
ACEA-1031
|
||||
| Synonyms |
Glystatin 1000 series member (1031), ACEA; Glystatin 1000 series member (1031), CoCensys
|
||||
| Indication | Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63] | Terminated | [1] | ||
| Company |
Acea Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c12c([N+](=O)[O-])c(c(cc2[nH]c(=O)c(=O)[nH]1)Br)Br
|
||||
| CAS Number |
CAS 153504-82-6
|
||||
| Target and Pathway | |||||
| Target(s) | NMDA receptor | Target Info | Modulator | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008256) | ||||
| REF 2 | In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 1995 Mar;47(3):568-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.